KYTX Kyverna Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$7.47

Period return

-0.80 (-9.67%)

Volume

615.8K

2026-06-05O $7.96 H $7.96 L $7.44 C $7.47MA5 $7.87MA20 $8.9MA60 $8.92MA120 $8.69

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.LowBUY22 days ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 14.LowBUY24 days ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 04. 23.LowBUYlast month
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $30.4 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Emeryville, CA, United States
Fiscal year end: —
Employees: 130
IPO date: —

View details →

2025. 12. 16.LowBUY6 months ago

Wells Fargo: Overweight